
-
Rallybio NASDAQ:RLYB Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut.
Location: | Website: rallybio.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-43.63M
Cash
75.14M
Avg Qtr Burn
-12.77M
Short % of Float
1.79%
Insider Ownership
4.06%
Institutional Own.
77.31%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RLYB212 Details Fetal and Neonatal Alloimmune Thrombocytopenia | Phase 2 Data readout | |
RLYB116 Details Myasthenia gravis, Paroxysmal nocturnal hemoglobinuria | Phase 1 Update | |
RLYB211 Details Fetal and Neonatal Alloimmune Thrombocytopenia | Failed Discontinued |